# Improve PAD PERformance With METformin

Study · id `cardio:ct-nct03054519` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03054519](<https://clinicaltrials.gov/study/NCT03054519>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03054519

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

## Technical summary

Registry record NCT03054519. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-23 (actual); primary completion 2025-08-20 (actual). Results posted on 2026-08-24.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 202 participants (enrolled count; ClinicalTrials.gov record NCT03054519, source copy `cardio:ctgov-nct03054519-2026-08-24`, retrieved 2026-10-31)
- Started: 2017-05-23 (actual) (ClinicalTrials.gov record NCT03054519, source copy `cardio:ctgov-nct03054519-2026-08-24`, retrieved 2026-10-31)
- Primary completion: 2025-08-20 (actual) (ClinicalTrials.gov record NCT03054519, source copy `cardio:ctgov-nct03054519-2026-08-24`, retrieved 2026-10-31)
- Completion: 2025-11-01 (actual) (ClinicalTrials.gov record NCT03054519, source copy `cardio:ctgov-nct03054519-2026-08-24`, retrieved 2026-10-31)
- Results first posted: 2026-08-24 (ClinicalTrials.gov record NCT03054519, source copy `cardio:ctgov-nct03054519-2026-08-24`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT03054519, source copy `cardio:ctgov-nct03054519-2026-08-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03054519-2026-08-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Improve PAD PERformance With METformin
- Acronym: PERMET
- Condition: Peripheral Artery Disease
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo
- Lead sponsor: Northwestern University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Northwestern University (`cardio:org-northwestern-university`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial (`cardio:pubmed-41205146`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: dd30c8252b780b72383efb93a35ecadc9c3229755fe645b5cf9c034a855bfb46
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
